This virtual symposium is designed to educate researchers, scientists, and health care providers in cancer genetics by presenting cutting-edge data from renowned researchers and clinicians. This symposium will provide new information on progress in cancer screening and prevention, as well as ongoing work in targeted therapy for BRCA1/2 and other mutation carriers through a series of lectures and panel discussions.

PROGRAM OBJECTIVES

At the completion of this symposium, attendees should be able to:
•Discuss new research on the genetic epidemiology of BRCA1/2 andother homologous recombination deficiency (HRD) genes.
•Describe current ethical, legal and social issues associated with carrying aBRCA1/2 mutation.
•Review new approaches to screening and prevention of hereditary breast,ovarian, pancreatic and prostate cancer.
•Discuss new advances in treatment for mutation carriers of BRCA1/2 andother known cancer susceptibility genes.

WHO SHOULD ATTEND

Healthcare providers including medical oncology, surgical oncology, gynecology oncology, OB-GYN, genetic counselors, primary care physicians and nurses/nurse practitioners who are interested in the genetics of BRCA1/2 related cancers.